Gallus A S, Chooi C C, Konetschnik F, Goodall K T
Thromb Res. 1984 Sep 1;35(5):513-26. doi: 10.1016/0049-3848(84)90283-4.
The effect of preoperative treatment with an estrogen containing oral contraceptive on the incidence of postoperative thrombosis (detected with 125I-fibrinogen leg scanning) was examined in 221 patients aged 18-49 years who had elective or emergency general intra-abdominal or gynecologic surgery, 99 of whom were taking an oral contraceptive before their operation. Eighty-five percent of the contraceptive treated patients had taken their preparation until 1-7 days before surgery and the rest until within a month of surgery; 81% were taking preparations containing 30 or 50 micrograms estrogen. Postoperative thrombosis developed in 1 of the 122 patients who were not taking a contraceptive and in none of the 99 contraceptive treated patients. As the 95% confidence limits for the 0% thrombosis rate observed in the contraceptive treated patients are 0-3.7%, the added risk of postoperative thrombosis attributable to oral contraceptive treatment before surgery is very small in young women who are otherwise at low risk of thrombosis. Plasma antithrombin level (by immunoassay), antithrombin activity (by chromogenic substrate assay), and antifactor Xa activity (by clotting assay), were measured before surgery in 81 patients, 42 of whom had been taking an oral contraceptive. Contraceptive treatment significantly reduced all 3 assay results. Its most marked effect was on antifactor Xa activity, which was reduced by contraceptive treatment from 103 +/- 24% (range 68 - 172%) to 81 +/- 27% (range 24 - 155%; with less than 80% activity in 54%, and less than 50% activity in 15% of patients). These results suggest that reduced preoperative antifactor Xa activity has a low specificity for thrombosis after moderately extensive surgery in young, otherwise fit, oral contraceptive treated women. This test is therefore unlikely to be a clinically useful predictor for postoperative thrombosis in this group of patients.
对221例年龄在18至49岁之间、接受择期或急诊普通腹部或妇科手术的患者,研究了术前使用含雌激素口服避孕药对术后血栓形成发生率(通过125I-纤维蛋白原腿部扫描检测)的影响。其中99例患者在手术前服用口服避孕药。85%服用避孕药的患者在手术前1至7天服用药物,其余患者在手术前一个月内服用;81%服用的是含30或50微克雌激素的制剂。122例未服用避孕药的患者中有1例发生术后血栓,而99例接受避孕药治疗的患者中无一例发生。由于在接受避孕药治疗的患者中观察到的0%血栓形成率的95%置信区间为0至3.7%,因此对于原本血栓形成风险较低的年轻女性,术前口服避孕药治疗导致术后血栓形成的额外风险非常小。对81例患者在手术前测量了血浆抗凝血酶水平(通过免疫测定)、抗凝血酶活性(通过发色底物测定)和抗Xa因子活性(通过凝血测定),其中42例患者一直在服用口服避孕药。避孕药治疗显著降低了所有三项检测结果。其最显著的影响是对抗Xa因子活性,接受避孕药治疗后,抗Xa因子活性从103±24%(范围68 - 172%)降至81±27%(范围24 - 155%);54%的患者活性低于80%,15%的患者活性低于50%。这些结果表明,术前抗Xa因子活性降低对于年轻、健康、接受口服避孕药治疗的女性在中度广泛手术后发生血栓形成的特异性较低。因此,该检测不太可能成为这组患者术后血栓形成的临床有用预测指标。